Perspective Therapeutics (NYSE:CATX) Stock Rating Lowered by Bank of America

Bank of America cut shares of Perspective Therapeutics (NYSE:CATX) from a buy rating to a neutral rating in a report published on Monday morning, Marketbeat.com reports. They currently have $5.00 price objective on the stock, down from their prior price objective of $24.00.

Several other analysts have also recently issued reports on the company. Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Finally, UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $4.12 on Monday. Perspective Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $19.05. The business has a 50 day moving average price of $10.78 and a 200-day moving average price of $12.32.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. As a group, research analysts forecast that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Insider Buying and Selling

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt bought 12,829 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the acquisition, the chief financial officer now owns 48,800 shares of the company’s stock, valued at approximately $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Johan M. Spoor purchased 14,500 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the purchase, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 33,595 shares of company stock valued at $126,625 over the last ninety days. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new stake in shares of Perspective Therapeutics during the third quarter valued at approximately $57,000. US Bancorp DE boosted its stake in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth $117,000. Point72 DIFC Ltd purchased a new position in shares of Perspective Therapeutics in the second quarter worth $118,000. Finally, Intech Investment Management LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at $137,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.